Medical 21

Medical 21 is a private, pre-revenue medical device innovator targeting a fundamental limitation in cardiovascular surgery: the need for vessel harvesting in bypass procedures. The company's core technology is the MAVERICS Graft, a biocompatible, nitinol-scaffold-based implant that leverages the body's regenerative pathways to guide the formation of a new, arterial-like blood vessel. By providing an off-the-shelf synthetic graft, Medical 21 seeks to expand patient eligibility, reduce procedure time and complications, and improve outcomes for the millions of patients undergoing CABG surgery worldwide, a field that has seen little innovation for over 60 years.

Regenerative synthetic graft platform utilizing a nitinol scaffold designed to stimulate angiogenesis and guide the body's formation of a new, arterial-like blood vessel for bypass procedures.

Direct competition for an off-the-shelf, small-diameter coronary graft is limited, as no such product is commercially available. The primary competition is the entrenched standard of care: autologous vessel harvesting (internal mammary artery, saphenous vein). Indirect competition includes other emerging tissue engineering approaches, drug-eluting stents for less severe disease, and other companies researching biohybrid or fully tissue-engineered vascular grafts, though none have reached the coronary market.